MX395317B - Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. - Google Patents

Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Info

Publication number
MX395317B
MX395317B MX2018000347A MX2018000347A MX395317B MX 395317 B MX395317 B MX 395317B MX 2018000347 A MX2018000347 A MX 2018000347A MX 2018000347 A MX2018000347 A MX 2018000347A MX 395317 B MX395317 B MX 395317B
Authority
MX
Mexico
Prior art keywords
antibodies
humanized
differentiation
chimeric cluster
chimeric
Prior art date
Application number
MX2018000347A
Other languages
English (en)
Other versions
MX2018000347A (es
Inventor
Isil Altintas
Janine Schuurman
Patrick Engelberts
Paul Parren
Rik Rademaker
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/050296 external-priority patent/WO2016110576A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of MX2018000347A publication Critical patent/MX2018000347A/es
Publication of MX395317B publication Critical patent/MX395317B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados o quiméricos que unen CD3. Adicionalmente se relaciona con anticuerpos biespecíficos, composiciones, composiciones farmacéuticas, uso de los anticuerpos en el tratamiento de una enfermedad y método de tratamiento.
MX2018000347A 2015-07-15 2016-07-14 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. MX395317B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201500413 2015-07-15
DKPA201500414 2015-07-15
DKPA201500416 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20
PCT/EP2016/066845 WO2017009442A1 (en) 2015-07-15 2016-07-14 Humanized or chimeric cd3 antibodies

Publications (2)

Publication Number Publication Date
MX2018000347A MX2018000347A (es) 2018-03-14
MX395317B true MX395317B (es) 2025-03-25

Family

ID=57757079

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000347A MX395317B (es) 2015-07-15 2016-07-14 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2022011002A MX2022011002A (es) 2015-07-15 2018-01-09 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011002A MX2022011002A (es) 2015-07-15 2018-01-09 Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.

Country Status (15)

Country Link
US (4) US11359015B2 (es)
EP (1) EP3322727B1 (es)
JP (3) JP2018526981A (es)
KR (2) KR102786353B1 (es)
CN (3) CN114989302B (es)
AU (2) AU2016293073B2 (es)
BR (1) BR112018000696A2 (es)
CA (1) CA2992380A1 (es)
EA (1) EA201890305A1 (es)
FI (1) FI3322727T3 (es)
IL (2) IL256562B2 (es)
MX (2) MX395317B (es)
NZ (1) NZ739028A (es)
UA (1) UA128057C2 (es)
WO (1) WO2017009442A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
HUE048722T2 (hu) 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
WO2018162749A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
CN111971298B (zh) 2018-03-12 2025-06-20 健玛保 抗体
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
US12377294B2 (en) * 2018-08-28 2025-08-05 Ambrx, Inc. Anti-CD3 antibody folate bioconjugates and their uses
JP7774447B2 (ja) * 2019-06-07 2025-11-21 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
EP4007772A4 (en) * 2019-07-29 2023-11-29 The Administrators Of The Tulane Educational Fund ANTIBODIES TO CANDIDA AND USES THEREOF
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CA3168613A1 (en) * 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
CA3176436A1 (en) * 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023003749A (es) * 2020-10-02 2023-04-24 Genmab As Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).
EP4334359A1 (en) 2021-05-07 2024-03-13 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US11814437B2 (en) * 2021-10-08 2023-11-14 Genmab A/S Antibodies binding to CD30 and CD3
CN115368446B (zh) * 2022-07-19 2025-08-08 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
CN102448984A (zh) 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN107827985A (zh) 2011-05-21 2018-03-23 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
HUE044633T2 (hu) 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
WO2013186613A1 (en) * 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
WO2013188693A1 (en) * 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
PT2869845T (pt) 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
HUE048722T2 (hu) * 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
UA120286C2 (uk) 2015-01-08 2019-11-11 Ґенмаб А/С Біспецифічне антитіло проти cd3 і cd20

Also Published As

Publication number Publication date
JP2025038049A (ja) 2025-03-18
AU2023201733A1 (en) 2023-07-13
AU2016293073A1 (en) 2018-02-01
US20220389101A1 (en) 2022-12-08
US11359015B2 (en) 2022-06-14
CN108368172A (zh) 2018-08-03
CA2992380A1 (en) 2017-01-19
JP2022023862A (ja) 2022-02-08
US20190284278A1 (en) 2019-09-19
CN114989302B (zh) 2025-08-05
FI3322727T3 (fi) 2026-03-17
IL256562A (en) 2018-02-28
EP3322727B1 (en) 2025-12-31
IL256562B2 (en) 2024-07-01
WO2017009442A1 (en) 2017-01-19
EA201890305A1 (ru) 2018-07-31
MX2018000347A (es) 2018-03-14
NZ778208A (en) 2025-05-02
JP2018526981A (ja) 2018-09-20
JP7604351B2 (ja) 2024-12-23
CN120842408A (zh) 2025-10-28
UA128057C2 (uk) 2024-03-27
KR20180030635A (ko) 2018-03-23
IL256562B1 (en) 2024-03-01
BR112018000696A2 (en) 2018-09-18
CN114989302A (zh) 2022-09-02
MX2022011002A (es) 2022-10-07
NZ778205A (en) 2025-05-02
CN108368172B (zh) 2022-06-14
IL310467A (en) 2024-03-01
EP3322727A1 (en) 2018-05-23
KR102786353B1 (ko) 2025-03-26
US20230027394A1 (en) 2023-01-26
KR20250048113A (ko) 2025-04-07
NZ739028A (en) 2023-05-26
US20220380464A1 (en) 2022-12-01
AU2016293073B2 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
PH12016501366A1 (en) Novel anti-baff antibodies
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201790342A1 (ru) Антитела к trem2 и способы их применения
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
SG10201901057UA (en) Anti-pd-l1 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
PH12019502694A1 (en) Anti-trkb antibodies
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
EA201892257A1 (ru) Анти-cd3 антитела и способы применения